SUBSCRIBE
SUBSCRIBE
News   FDA

Bristol-Myers Squibb Company: ONGLYZATM (saxagliptin) Receives Marketing Authorisation In Europe For The Treatment Of Type 2 Diabetes

October 5, 2009 | 
1 min read
PARIS & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE/LSE: AZN) announced today that the European Commission has granted marketing authorisation for ONGLYZATM in the 27 countries of the European Union.
FDA Approvals Europe
Bristol Myers Squibb Company
MORE ON THIS TOPIC
Opinion
The next FDA commissioner must be a champion for gene therapies
June 5, 2026
 · 
4 min read
 · 
Erik Paulsen
Time on the hourglass stopped. Clock on table. Pause in business, collapse.
Regulatory
Stakeholders want Makary’s voucher program paused, call for FDA independence
June 5, 2026
 · 
3 min read
 · 
Tristan Manalac
Medication Warning: Yellow Caution Sign with Scattered Capsules
Manufacturing
FDA hits Medline with warning letter over long-running contamination problem
June 3, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Digital compass. Business strategic explorer, Vision crisis, Mission path, Agency creative, Digital strategy, Market decision, Achievement strategy, Financial stock, Company vision concepts
Policy
FDA taps prior knowledge to expedite cell and gene therapy development
June 3, 2026
 · 
12 min read
 · 
BioSpace Editorial Staff